Last updated: September 5, 2026
Brompheniramine maleate and pseudoephedrine hydrochloride is a mature combination used for temporary relief of nasal congestion, runny nose, sneezing, and related upper-respiratory symptoms. The U.S. market is primarily generic and fragmented between prescription oral solutions and over-the-counter products sold under monograph conditions. Patent risk is negligible. Commercial performance depends on retail distribution, pseudoephedrine purchasing restrictions, seasonal respiratory demand, pediatric formulation access, and manufacturing reliability rather than exclusivity.
No standalone public revenue series tracks the combination consistently. Sales are divided among prescription products, OTC brands, private-label products, and combination products containing additional active ingredients such as dextromethorphan.
What products contain brompheniramine maleate and pseudoephedrine hydrochloride?
The combination is available in oral liquid, tablet, and capsule products, although the exact strengths and regulatory status vary by product.
| Product category |
Typical market position |
Regulatory pathway |
Commercial profile |
| Brompheniramine/pseudoephedrine oral solution |
Prescription and generic |
NDA or ANDA, depending on product |
Pediatric and family-care demand |
| Brompheniramine/pseudoephedrine/dextromethorphan solution |
Prescription combination |
NDA or ANDA |
Cough-and-cold positioning |
| OTC brompheniramine/pseudoephedrine products |
Retail pharmacy and mass market |
OTC monograph or approved legacy product |
Brand and private-label competition |
| Tablet and capsule products |
OTC retail |
OTC monograph framework or approved applications |
Lower manufacturing complexity |
| Store-brand products |
Retailer-controlled |
Contract-manufactured |
Price-sensitive, high substitution |
Brompheniramine is a first-generation antihistamine. Pseudoephedrine is an oral sympathomimetic decongestant. Products commonly use brompheniramine maleate and pseudoephedrine hydrochloride as the salt forms.
Prescription liquids frequently use a concentration of 2 mg brompheniramine maleate and 30 mg pseudoephedrine hydrochloride per 5 mL, although labeling must be reviewed product by product. Some commercial products add dextromethorphan hydrobromide.
What is the FDA regulatory status of brompheniramine and pseudoephedrine products?
FDA regulation is split between prescription approvals and the OTC drug-monograph system.
Pseudoephedrine is an established oral nasal decongestant active ingredient. Brompheniramine is an established antihistamine active ingredient. FDA OTC rules recognize both ingredients for cold, allergy, and nasal-congestion applications subject to dosage, labeling, combination, and safety requirements under the OTC framework.[1]
Products marketed as prescription drugs generally require an approved NDA or ANDA. Products marketed under OTC conditions must comply with the applicable monograph requirements, including permitted active ingredients, doses, indications, warnings, and labeling.
Pseudoephedrine also carries a separate supply-chain burden under the Combat Methamphetamine Epidemic Act. Retail sales are subject to daily and monthly quantity limits, identification requirements, logbook obligations, and behind-the-counter controls.[2] These requirements increase retailer and distributor compliance costs and affect product placement.
What patents protect brompheniramine maleate and pseudoephedrine hydrochloride?
The active ingredients are off-patent. The basic chemical composition of brompheniramine and pseudoephedrine does not provide a meaningful current exclusivity barrier in the United States.
| IP category |
Current commercial significance |
| Active-ingredient patents |
No meaningful blocking exclusivity |
| Original combination patents |
Historical rights are expired |
| Basic oral-solution formulations |
Generally low protection value |
| Method-of-use patents |
Limited relevance for routine cold and allergy indications |
| Manufacturing patents |
Possible process know-how, but limited market exclusivity |
| Trademark rights |
Relevant to brand pricing but not generic entry |
| Trade secrets |
Potentially relevant to taste, stability, and manufacturing yield |
The commercial value of the product is therefore not based on a live composition patent. Manufacturers compete through FDA approval, supply reliability, customer contracts, private-label relationships, formulation quality, and distribution.
When does brompheniramine-pseudoephedrine lose exclusivity?
The combination lost meaningful market exclusivity many years ago. Current products do not depend on a near-term patent-expiration event.
For prescription versions, any remaining exclusivity is product-specific and must be evaluated through the FDA’s Orange Book and the relevant approved labeling. The Orange Book identifies patents and regulatory exclusivity associated with approved prescription drug products, but it does not create market protection for the active ingredients themselves.[3]
A generic manufacturer can generally compete through an ANDA when the reference product has the required approval pathway and the applicant satisfies FDA requirements. For OTC products, competition is usually governed by monograph compliance rather than a Paragraph IV patent challenge.
How many patents cover brompheniramine-pseudoephedrine products?
There is no commercially important patent estate comparable to those surrounding new molecular entities, complex injectables, inhaled therapies, or biologics.
A product-specific review may identify historical patents, formulation filings, trademarks, or patents associated with a particular branded product. Those rights do not generally prevent broad generic and private-label competition. The important distinction is between:
- Patents listed against a specific approved prescription product;
- Expired historical patents covering the active ingredients or combinations;
- Manufacturing or formulation patents that may have narrow claim scope; and
- Trademarks that protect brand identity but do not block substitute products.
The practical freedom-to-operate risk is low for standard oral tablets and liquids. Risk rises modestly where a manufacturer uses a differentiated delivery system, preservative system, flavor technology, or proprietary packaging.
Are there Paragraph IV challenges for brompheniramine-pseudoephedrine?
Paragraph IV litigation is not a central market issue for this combination.
A Paragraph IV certification applies when an ANDA applicant challenges a listed patent for a prescription reference drug. Because brompheniramine-pseudoephedrine products are mature and commonly generic, the economic incentive to initiate a high-cost patent challenge is limited. The relevant commercial pathway is usually abbreviated approval, contract manufacturing, or OTC monograph compliance.
Potential litigation is more likely to involve:
- Product liability;
- Labeling and pediatric dosing;
- Manufacturing defects;
- Trademark disputes;
- Distribution contracts;
- Drug shortages or allocation practices; and
- State-level restrictions involving pseudoephedrine sales.
No biosimilar pathway applies. Brompheniramine-pseudoephedrine is a small-molecule drug, not a biologic. FDA biosimilar competition is therefore irrelevant to the product’s competitive structure.[4]
What formulation patents protect brompheniramine-pseudoephedrine liquids?
Formulation protection is limited and usually narrow. Potentially protectable features include:
- Taste-masking systems;
- Alcohol-free or sugar-free liquids;
- Preservative combinations;
- Color and flavor systems;
- Improved chemical stability;
- Pediatric dosing devices;
- Unit-dose packaging;
- Modified-release delivery; and
- Compatibility with high-throughput filling equipment.
These features can support product differentiation but rarely create durable market exclusivity. Most oral liquids remain substitutable if they contain the same active ingredients, strength, dosage form, and permitted indications.
The principal manufacturing barriers are operational rather than legal. Liquid products require validated blending, microbial control, preservative performance, container-closure integrity, viscosity control, fill-volume accuracy, and stability testing. These requirements can exclude poorly capitalized entrants but do not prevent established generic manufacturers from competing.
How does pseudoephedrine regulation affect market dynamics?
Pseudoephedrine controls have a greater effect on commercial execution than patent law.
Retailers must manage sales limits, identity verification, electronic or paper transaction records, employee training, and inventory controls. States may impose additional restrictions. These measures create several effects:
- Lower convenience compared with phenylephrine or non-decongestant alternatives;
- Reduced impulse purchasing;
- Greater importance for pharmacy-counter distribution;
- Higher compliance costs for retailers;
- More complex e-commerce fulfillment; and
- Higher risk of product substitution when inventory is unavailable.
The restrictions also make distribution relationships strategically important. A supplier with reliable compliance systems and broad pharmacy access can outperform a lower-cost manufacturer with weaker retail execution.
FDA’s 2023 proposal to remove oral phenylephrine as an effective OTC nasal decongestant could affect the broader decongestant market if finalized, although it would not directly remove pseudoephedrine from the market.[5] Any shift away from oral phenylephrine could support pseudoephedrine demand, but purchasing restrictions would remain a constraint.
What is the competitive landscape for brompheniramine-pseudoephedrine?
Competition is broad and price-driven. Relevant substitutes include:
- Loratadine-pseudoephedrine;
- Cetirizine-pseudoephedrine;
- Chlorpheniramine-pseudoephedrine;
- Phenylephrine-containing products;
- Intranasal corticosteroids;
- Intranasal antihistamines;
- Non-decongestant antihistamines; and
- Combination cough, cold, and flu products.
Brompheniramine is a sedating first-generation antihistamine. That characteristic supports use in selected cold and allergy products but limits its attractiveness for consumers seeking non-sedating daily allergy treatment.
The combination is most commercially defensible in:
- Pediatric and family-care channels;
- Prescription liquid products;
- Private-label retail programs;
- Seasonal cold-and-flu displays;
- Pharmacies serving acute-care customers; and
- Products with recognizable taste and dosing convenience.
Its weakest position is in chronic allergy treatment, where second-generation antihistamines and intranasal therapies have stronger consumer acceptance.
What is the financial trajectory for brompheniramine-pseudoephedrine?
The financial trajectory is mature, low-growth, and highly fragmented.
| Financial driver |
Expected effect |
| Unit demand |
Seasonal and broadly stable |
| Price |
Downward pressure from generic substitution |
| Gross margin |
Moderate to low for commodity products |
| Brand premium |
Available only with strong distribution or formulation differentiation |
| Regulatory cost |
Elevated by pseudoephedrine controls |
| Supply risk |
Moderate, especially for liquids and contract-manufactured products |
| Patent risk |
Low |
| Launch opportunity |
Incremental rather than transformational |
| Revenue visibility |
Limited because sales are dispersed across suppliers |
Revenue is likely to follow respiratory-season patterns rather than a durable growth curve. Demand can rise during periods of elevated cold, influenza, or other respiratory illness activity, then normalize. Pediatric liquid demand may show stronger seasonal movement than tablet demand.
A manufacturer entering the category should not expect pharmaceutical-style returns from exclusivity. The more realistic investment thesis is operational: win retailer contracts, secure active-ingredient supply, maintain high service levels, and offer multiple package sizes or dosage forms.
What generic launch scenarios exist?
The most likely launch scenarios are:
Private-label OTC launch
A retailer or consumer-health company commissions an established contract manufacturer. This is the lowest-differentiation model and depends on price, compliance, and shelf access.
Generic prescription oral-solution launch
A manufacturer files or acquires an ANDA for a reference product. The commercial opportunity is greater than for an undifferentiated OTC tablet if the product has stable pharmacy demand, but the market remains price competitive.
Combination-product launch
A product adds dextromethorphan or another permitted active ingredient. This may increase consumer relevance but also raises formulation, labeling, and regulatory complexity.
Premium formulation launch
An alcohol-free, sugar-free, better-tasting, or unit-dose liquid can command better placement or contract economics. The benefit is commercial differentiation, not durable patent exclusivity.
Supply-constrained entry
A company can gain share during a shortage or allocation period. Such gains may reverse when incumbent supply recovers.
What patent litigation affects brompheniramine-pseudoephedrine?
No major patent-litigation structure currently defines the category. Litigation exposure is more likely to arise from product liability, FDA enforcement, manufacturing quality, trademark use, or distribution disputes than from an active composition patent.
For diligence, the relevant review should include the FDA Orange Book for prescription reference products, FDA drug-shortage records, labeling histories, manufacturing inspection records, and federal or state litigation databases.[3,6]
How strong is the patent estate for brompheniramine-pseudoephedrine?
The patent estate is weak from an exclusivity perspective and moderate only as an operational barrier.
| Dimension |
Assessment |
| Composition protection |
Weak or expired |
| Method-of-use protection |
Weak |
| Standard formulation protection |
Weak |
| Specialty formulation protection |
Potentially moderate but narrow |
| Manufacturing know-how |
Moderate |
| Trademark protection |
Product-specific |
| Regulatory moat |
Moderate for compliant suppliers |
| Supply-chain moat |
Moderate where pseudoephedrine controls or liquid capacity constrain supply |
The category rewards execution more than invention. A company’s defensibility depends on approved manufacturing capacity, retailer access, quality systems, formulation reliability, and cost control.
Key Takeaways
- Brompheniramine maleate and pseudoephedrine hydrochloride is a mature, genericized combination.
- Active-ingredient patent protection is not a meaningful barrier.
- Paragraph IV activity and biosimilar risk are both limited or irrelevant.
- FDA status depends on whether the product is marketed under an approved prescription application or OTC monograph conditions.
- Pseudoephedrine purchasing controls create meaningful distribution and compliance costs.
- Oral liquids offer more differentiation than standard tablets but remain difficult to protect through broad patents.
- Financial performance is seasonal, fragmented, and dependent on volume, retailer access, and supply reliability.
- The strongest commercial opportunities are private-label contracts, prescription liquids, and differentiated pediatric formulations.
- The category is unsuitable for a high-exclusivity investment thesis but can support stable cash generation for efficient manufacturers.
FAQs
Is brompheniramine-pseudoephedrine still commercially relevant?
Yes. It remains relevant in cold, allergy, pediatric, and prescription oral-liquid channels, although it competes with newer antihistamines and alternative decongestants.
Is brompheniramine-pseudoephedrine a controlled substance?
The combination is not a controlled substance in the same manner as opioid drugs. Pseudoephedrine is subject to federal retail-sale controls because it can be diverted for illicit methamphetamine production.[2]
Can a company launch a generic brompheniramine-pseudoephedrine product without a patent license?
Generally, an entrant does not need a license to expired composition patents. The company must still satisfy the applicable FDA approval or OTC monograph requirements and avoid infringement of any live product-specific rights.
Which dosage form has the best commercial opportunity?
Oral liquids generally offer more differentiation than standard tablets because taste, dosing accuracy, preservative systems, and pediatric usability affect purchasing decisions. They also impose higher manufacturing and quality-control costs.
Does the product have biosimilar competition?
No. Biosimilar rules apply to biological products. Brompheniramine-pseudoephedrine is a small-molecule combination and competes through generic, OTC, and private-label pathways.
References
- U.S. Food and Drug Administration. (2023). Over-the-counter monograph M012: Cold, cough, allergy, bronchodilator, and anti-asthmatic drug products. https://www.fda.gov
- U.S. Drug Enforcement Administration. (n.d.). Pseudoephedrine: Federal retail sales requirements. https://www.dea.gov
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Biosimilar and interchangeable biosimilar products. https://www.fda.gov
- U.S. Food and Drug Administration. (2023). FDA proposes removing oral phenylephrine from OTC monograph. https://www.fda.gov
- U.S. Food and Drug Administration. (2024). Drug shortages. https://www.fda.gov
